




Supplementary Figure S1: Flowchart illustrating the selection and inclusion of patients in the study.




Supplementary Figure S2: Kaplan-Meier curves for progression-free survival (PFS) during first-line treatment (A) and overall survival (OS) (B) in patients with classical versus basal-like subtypes.



Supplementary Figure S3: Immunohistochemical characteristics of the classical subtype. GATA6 immunohistochemistry: nuclear staining intensity of 2, 50% positive tumor cells, and H-score of 100, image at 40x magnification (A). CK17 immunohistochemistry: membrane staining intensity of 0, 0% positive tumor cells, and H-score of 0, image at 40x magnification (B).



Supplementary Figure S4: Immunohistochemical characteristics of the basal-like subtype. GATA6 immunohistochemistry: nuclear staining intensity of 0, 0% positive tumor cells, and H-score of 0, image at 40x magnification (A). CK17 immunohistochemistry: membrane staining intensity of 1, 70% positive tumor cells, and H-score of 70, image at 40x magnification (B).



Supplementary Figure S5: Immunohistochemistry for the mixed subtype. GATA6 immunohistochemistry: nuclear staining Intensity of 3, 90% positive tumor cells, and H-Score of 270, image at 40x magnification (A). CK17 immunohistochemistry: membrane staining intensity of 2, 75% positive tumor cells, and H-Score of 150, image at 40x magnification (B).

